Daré Bioscience (NASDAQ:DARE) Stock Rating Lowered by Brookline Capital Management

Daré Bioscience (NASDAQ:DARE) was downgraded by stock analysts at Brookline Capital Management from a “buy” rating to a “hold” rating in a research note issued on Wednesday, MarketBeat.com reports.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Daré Bioscience in a report on Monday, April 1st. Dawson James cut Daré Bioscience from a “buy” rating to a “neutral” rating in a report on Tuesday, January 30th.

Daré Bioscience Stock Down 41.7 %

DARE stock opened at $0.28 on Wednesday. The business has a fifty day moving average price of $0.46 and a 200 day moving average price of $0.40. Daré Bioscience has a fifty-two week low of $0.27 and a fifty-two week high of $1.10.

Institutional Investors Weigh In On Daré Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in DARE. Bank of New York Mellon Corp acquired a new stake in shares of Daré Bioscience in the 1st quarter valued at $34,000. Citigroup Inc. acquired a new stake in shares of Daré Bioscience in the 1st quarter valued at $40,000. BlackRock Inc. increased its stake in shares of Daré Bioscience by 63.7% in the 1st quarter. BlackRock Inc. now owns 602,036 shares of the biotechnology company’s stock valued at $897,000 after buying an additional 234,243 shares during the period. Vanguard Group Inc. increased its stake in shares of Daré Bioscience by 13.0% in the 1st quarter. Vanguard Group Inc. now owns 3,453,021 shares of the biotechnology company’s stock valued at $5,145,000 after buying an additional 396,968 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Daré Bioscience during the first quarter worth $150,000. 6.70% of the stock is owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.